UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 8,479 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC trimmed its position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) by 15.1% in the third quarter, according to its most recent filing with the SEC. The institutional investor owned 47,714 shares of the company’s stock after selling 8,479 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Axsome Therapeutics were worth $4,288,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Northwestern Mutual Wealth Management Co. bought a new position in shares of Axsome Therapeutics during the 2nd quarter valued at approximately $27,000. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Axsome Therapeutics during the 2nd quarter valued at approximately $47,000. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Axsome Therapeutics by 22.4% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,736 shares of the company’s stock valued at $156,000 after acquiring an additional 318 shares during the period. Moors & Cabot Inc. bought a new position in shares of Axsome Therapeutics during the 3rd quarter valued at approximately $200,000. Finally, Whalen Wealth Management Inc. bought a new position in shares of Axsome Therapeutics during the 3rd quarter valued at approximately $236,000. 81.49% of the stock is owned by institutional investors.

Axsome Therapeutics Stock Performance

NASDAQ AXSM opened at $94.37 on Friday. Axsome Therapeutics, Inc. has a 1 year low of $64.11 and a 1 year high of $105.00. The company has a debt-to-equity ratio of 1.97, a current ratio of 2.44 and a quick ratio of 2.37. The stock has a market capitalization of $4.57 billion, a PE ratio of -14.45 and a beta of 1.18. The company’s 50 day simple moving average is $92.95 and its two-hundred day simple moving average is $87.21.

Axsome Therapeutics (NASDAQ:AXSM) last posted its earnings results on Tuesday, November 12th. The company reported ($1.34) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.38) by $0.04. Axsome Therapeutics had a negative net margin of 91.87% and a negative return on equity of 158.36%. The business had revenue of $104.76 million for the quarter, compared to analysts’ expectations of $98.71 million. During the same period in the prior year, the company posted ($1.32) EPS. Analysts predict that Axsome Therapeutics, Inc. will post -4.6 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on AXSM shares. Wells Fargo & Company started coverage on shares of Axsome Therapeutics in a research report on Tuesday, September 3rd. They set an “overweight” rating and a $140.00 target price for the company. Robert W. Baird upped their price target on shares of Axsome Therapeutics from $112.00 to $116.00 and gave the company an “outperform” rating in a research note on Wednesday, November 13th. Needham & Company LLC restated a “buy” rating and set a $130.00 price target on shares of Axsome Therapeutics in a research note on Tuesday, November 12th. HC Wainwright restated a “buy” rating and set a $180.00 price target on shares of Axsome Therapeutics in a research note on Monday, November 25th. Finally, StockNews.com upgraded shares of Axsome Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, November 20th. One investment analyst has rated the stock with a hold rating and fourteen have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $125.93.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.